MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 85 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2023. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,352,250 | +277.6% | 234,250 | +237.8% | 0.03% | +237.5% |
| Q2 2023 | $3,536,391 | -16.4% | 69,341 | -64.9% | 0.01% | -27.3% |
| Q1 2023 | $4,228,953 | +84.8% | 197,707 | -9.3% | 0.01% | +83.3% |
| Q4 2022 | $2,288,990 | +187.9% | 217,999 | +118.3% | 0.01% | +200.0% |
| Q3 2022 | $795,000 | – | 99,874 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,109,315,484 | 30.92% |
| Cormorant Asset Management, LP | 8,142,100 | $415,247,100 | 23.26% |
| Ally Bridge Group (NY) LLC | 91,413 | $4,662,063 | 5.65% |
| Ghost Tree Capital, LLC | 330,000 | $16,830,000 | 5.56% |
| Finepoint Capital LP | 302,000 | $15,402,000 | 5.33% |
| 5AM Venture Management, LLC | 357,486 | $18,231,786 | 4.54% |
| Altium Capital Management LP | 88,000 | $4,488,000 | 3.40% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,200,000 | 3.16% |
| MPM BioImpact LLC | 295,111 | $15,050,661 | 3.03% |
| HighVista Strategies LLC | 129,722 | $6,615,822 | 3.03% |